TB diagnostic tests: how do we figure out their costs?

References

• WHO. Global tuberculosis control: epidemiology, strategy, financing: WHO Report 2009. WHO/HTM/TB/2009.411. WHO, Geneva, Switzerland, 1–303 (2009).
   Google Scholar
• Lopez AD, Mathers CD (Eds.) Global Burden of Disease and Risk Factors. Oxford University Press, NY, USA (2006).
   Google Scholar
• WHO. The Global MDR-TB and XDR-TB Response Plan, 2007–2008. WHO/HTM/TB/2007.387. WHO. Geneva, Switzerland (2007).
   Google Scholar
• Young DB, Perkins MD, Duncan K et al. Confronting the scientific obstacles to global control of tuberculosis. J. Clin. Invest.118(4), 1255–1265 (2008).
   PubMed Web of Science ®Google Scholar
• Keeler E, Perkins MD, Small P et al. Reducing the global burden of tuberculosis: the contribution of improved diagnostics. Nature.444(Suppl. 1), 49–57 (2006).
   PubMedGoogle Scholar
• Pai M, Ramsay A, O’Brien R. Evidence based tuberculosis diagnosis. PLoS Med.5(7), e156 (2008).
   Google Scholar
• Pai M, O’Brien R. New diagnostics for latent and active tuberculosis: state of the art and future prospects. Semin. Respir. Crit. Care Med.29(5), 560–568 (2008).
   PubMedGoogle Scholar
• WHO. New WHO policies. The use of liquid medium for culture and DST. Policy statement (2007).
   Google Scholar
• WHO. Molecular line probe assays for rapid screening of patients at risk of multidrug-resistant tuberculosis (MDR-TB). Policy statement (2008).
   Google Scholar
• WHO and Foundation for Innovative New Diagnostics. Diagnostics for tuberculosis: global demand and market potential. WHO, Geneva, Switzerland (2006).
   Google Scholar
• Canadian Agency for Drugs and Technologies in Health. Guidelines for the Economic Evaluation of Health Technologies: Canada (3rd Edition). Ottawa, Canada (2006).
   Google Scholar
• Kivihya-Ndugga LEA, van Cleeff MRA, Githui WA et al. A comprehensive comparison of Ziehl-Neelsen and fluorescence microscopy for the diagnosis of tuberculosis in a resource-poor urban setting. Int. J. Tuberc. Lung Dis.7, 1163–1171 (2003).
   PubMedGoogle Scholar
• Sohn H, Sinthuwattanawibool C, Rienthong S et al. Fluorescence microscopy is less expensive than Ziehl-Neelsen microscopy in Thailand. Int. J. Tuberc. Lung Dis.13(2), 266–269 (2009).
   PubMedGoogle Scholar
• de Perio MA, Tsevat J, Roselle GA et al. Cost–effectiveness of interferon-g release assays vs tuberculin skin tests in health care workers. Arch. Intern. Med.169(2), 179–187 (2009).
   PubMed Web of Science ®Google Scholar
• Marra F, Marra CA, Sadatsafavi M et al. Cost–effectiveness of a new interferon-based blood assay, QuantiFERON®-TB Gold, in screening tuberculosis contacts. Int. J. Tuberc. Lung Dis.12(12), 1414–1424 (2009).
   Google Scholar
• Oxlade O, Schwartzman K, Menzies D. Interferon-g release assays and TB screening in high-income countries: a cost–effectiveness analysis. Int. J. Tuberc. Lung Dis.11(1), 16–25 (2007).
   PubMed Web of Science ®Google Scholar
• Dowdy DW, Maters A, Parrish N et al. Cost–effectiveness analysis of the gen-probe amplified Mycobacterium tuberculosis direct test as used routinely on smear-positive respiratory specimens. J. Clin. Microbiol.41(3), 948–953 (2003).
   PubMedGoogle Scholar
• Mueller DH, Mwenge L, Muyoyeta M et al. Costs and cost–effectiveness of tuberculosis cultures using solid and liquid media in a developing country. Int. J. Tuberc. Lung Dis.12(10), 1196–1202 (2008).
   PubMedGoogle Scholar
• Acuna-Villaorduna C, Vassall A, Henostroza G et al. Cost–effectiveness analysis of introduction of rapid, alternative methods to identify multidrug-resistant tuberculosis in middle-income countries. Clin. Infect. Dis.47(4), 487–495 (2008).
   PubMed Web of Science ®Google Scholar
• Mitchison DA. Bacteriology of tuberculosis. Trop. Doct.4(4), 147–153 (1974).
   PubMedGoogle Scholar
• Drummond MF, O’Brien B, Stoddart GL et al.Methods for the Economic Evaluation of Health Care Programmes (2nd Edition). Oxford University Press, Oxford, UK (1997).
   Google Scholar
• Adam T, Baltussen R, Tan-Torres T et al. Making choices in health: WHO guide to cost–effectiveness analysis. WHO, Geneva, Switzerland (2003).
   Google Scholar
• Buchanan JM. Opportunity cost. In: The New Palgrave: A Dictionary of Economics, (Volume 3) Durlauf SN, Blume LE (Eds.) Palgrave Macmillan, UK 718–721 (1987).
   Google Scholar
• Creese A, Parker D. Cost analysis in primary health care: a training manual for programme managers. WHO, Geneva, Switzerland (1994).
   Google Scholar
• Walker D, Kumaranayake L. Allowing for differential timing in cost analyses: discounting and annualization. Health Policy and Planning17(1), 112–118 (2002).
   PubMed Web of Science ®Google Scholar
• Kumaranayake L. The real and the nominal? Making inflationary adjustments to cost and other economic data. Health Policy and Planning15, 230–234 (2000).
   PubMed Web of Science ®Google Scholar
• Pai M, O’Brien R. Tuberculosis diagnostics trials: do they lack methodological rigor? Expert Rev. Mol. Diagn.6(4), 509–514 (2006).
   PubMed Web of Science ®Google Scholar